1 active not recruiting, 1 terminated. 2 Phase 1, 1 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 2 | Active not recruiting 1, Terminated 1 |
| Phase 2 | 1 | Active not recruiting 1 |
Follow EGFR Exon 20 Mutation: new trials by email Literature Review of EGFR Exon 20 Mutation trials Research Report on EGFR Exon 20 Mutation
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| (Concerto) Study of BLU-451 in Advanced Cancers With EGFR Exon 20 Insertion Mutations BLU-451, Carboplatin, Pemetrexed - Lung Neoplasm Malignant, Carcinoma, Non-Small-Cell Lung | Phase 1 | Terminated | Blueprint Medicines Corporation | 103 | 2022-03-04 | 2025-02-10 |
| A Phase 1/2 Trial of CLN-081 in Patients With Non-Small Cell Lung Cancer CLN-081 - Non Small Cell Lung Cancer, EGFR Exon 20 Mutation | Phase 1 / Phase 2 | Active not recruiting | Cullinan Therapeutics Inc. | 284 | 2019-10-31 | 2026-06-17 |
Carcinoma, Non-Small-Cell Lung (2) · Adenocarcinoma (1) · Brain Neoplasms (1) · Bronchial Neoplasms (1) · Carcinoma (1) · Carcinoma, Bronchogenic (1) · Lung Diseases (1) · Lung Neoplasms (1) · Neoplasms (1) · Neoplasms by Histologic Type (1) · Neoplasms by Site (1) · Respiratory Tract Diseases (1) · Respiratory Tract Neoplasms (1) · Thoracic Neoplasms (1)
Brain Diseases (1) · Bronchial Diseases (1) · Bronchial Neoplasms (1) · Carcinoma, Bronchogenic (1) · Central Nervous System Diseases (1) · Central Nervous System Neoplasms (1) · Lung Diseases (1) · Lung Neoplasms (1) · Neoplasms (1) · Neoplasms by Site (1) · Neoplasms, Glandular and Epithelial (1) · Nervous System Diseases (1) · Nervous System Neoplasms (1) · Respiratory Tract Diseases (1) · Respiratory Tract Neoplasms (1)
Carboplatin (1) · Pemetrexed (1) · zipalertinib (1)
Blueprint Medicines Corporation (1) · Cullinan Therapeutics Inc. (1)
Japan (2) · South Korea (2) · Taiwan (2) · United States (2) · Canada (1) · Hong Kong (1) · Italy (1) · Netherlands (1) · Singapore (1) · Spain (1)